Semaglutide vs. Tirzepatide
This is the rare peptide comparison with real head-to-head evidence. Both molecules are FDA-approved, both went through massive trial programs, and a direct comparison trial (SURMOUNT-5) has actually been run — so the honest answer here is unusually specific.
Semaglutide (Ozempic, Wegovy) activates the GLP-1 receptor. Tirzepatide (Mounjaro, Zepbound) activates GLP-1 and GIP receptors together. Both slow stomach emptying, signal fullness, and improve glycemic control; the second receptor is tirzepatide's bet, and the trial data suggests the bet pays.
The facts, side by side
| Semaglutide | Tirzepatide | |
|---|---|---|
| Regulatory status | FDA-approved drug | FDA-approved drug |
| Evidence level | Human clinical trials | Human clinical trials |
| Category | Weight Loss | Weight Loss |
Full profiles: Semaglutide · Tirzepatide
Average weight loss in trials
In SURMOUNT-5, the head-to-head trial in adults with obesity, average weight loss was greater with tirzepatide than semaglutide (roughly 20% vs 14% over 72 weeks). Averages are not personal predictions — responses spread widely around them in both arms.
Evidence maturity
Semaglutide has the longer record: more years on market, cardiovascular-outcome trials completed, enormous real-world exposure. Tirzepatide's data is newer but growing fast. Neither is an evidence risk; semaglutide simply has more history.
Side effects
Both lists are dominated by GI effects — nausea, constipation, diarrhea — that cluster during dose escalation. Trial discontinuation rates were broadly similar. Individual tolerance differs and isn't predictable in advance.
Cost and access
Both are expensive brand drugs whose out-of-pocket reality depends on insurance, savings programs and indication. Which one a plan covers is frequently the deciding factor in practice — a coverage question, not a science question.
The bottom line
Tirzepatide produced larger average weight loss in the head-to-head trial; semaglutide carries the longer track record and cardiovascular-outcomes data. Both are legitimate, well-evidenced prescription medicines — which one fits a given patient is a prescriber-and-insurance conversation, not a forum verdict.
Semaglutide vs. Tirzepatide FAQ
Which is better for weight loss, semaglutide or tirzepatide?
In the SURMOUNT-5 head-to-head trial, tirzepatide's average weight loss was greater. Averages aren't individual guarantees, and tolerability, coverage and medical history all move the answer for a specific person.
Can you switch from semaglutide to tirzepatide?
Prescribers do manage transitions between GLP-1-class drugs; how is a clinical decision involving dose mapping and timing. It's a common, answerable question for the prescriber managing your care.
Are compounded versions of these drugs the same thing?
Compounded versions exist through licensed pharmacies under specific conditions, but they are not FDA-approved products, and the shortage conditions that permitted mass compounding have narrowed. Source and oversight are the differences that matter.
More comparisons
Tirzepatide vs. Retatrutide
One is an FDA-approved medicine; the other is an investigational triple agonist still in trials. The comparison that matters is regulatory status, not receptor count.
Semaglutide vs. Liraglutide
Two generations of the same drug class: how the weekly GLP-1 compares with its daily predecessor on results, track record and — increasingly — cost.
BPC-157 vs. TB-500
The internet's two favorite healing peptides compared honestly: different molecules, similar marketing, and the same missing ingredient — controlled human trials.
Build your own comparison